Hemo Organic Limited reported a widened net loss of ₹77.81 lakh for the financial year ended March 31, 2026, compared to a net loss of ₹16.39 lakh in the previous year. Revenue from operations for FY26 stood at ₹93.10 lakh, a significant decline from ₹241.43 lakh in FY25. The company's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, at a meeting held on May 29, 2026.

Qualified Audit Opinion

The statutory auditor, MAAK & Associates, issued a qualified opinion on the annual financial results. The firm stated it was not provided with balance confirmations or other details for trade receivables, trade payables, and loans & advances. Consequently, the auditors were unable to determine whether adjustments were necessary for recorded or unrecorded transactions impacting the balance sheet and profit and loss statement.

Deferred Tax Asset Reversal

The financial statements include an emphasis of matter paragraph regarding the reversal of Deferred Tax Assets amounting to ₹27.93 lakh. This reversal was based on management's reassessment of future taxable profits and the company's continued losses, concluding that sufficient certainty regarding recoverability no longer exists under Ind AS 12.

Financial Performance

For the quarter ended March 31, 2026, the company reported a net loss of ₹50.57 lakh on a total income of ₹92.70 lakh. In the corresponding quarter of the previous year, it had posted a profit of ₹37.34 lakh on a total income of ₹250.38 lakh. The total comprehensive income for FY26 was a loss of ₹77.81 lakh.

Capital Raising and Going Concern

During the quarter, the company allotted 34,00,000 convertible warrants on a preferential basis to non-promoters at a price of ₹12.50 each, including a premium of ₹2.50. The company received ₹106.25 lakh, representing 25% of the subscription price. The notes to the accounts state that accumulated losses exceeded paid-up capital and reserves as of March 31, 2026, and current liabilities exceeded current assets, indicating material uncertainty about the company's ability to continue as a going concern.

Hemo organic Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2026.

Regulatory Compliance Submission

The company submitted the compliance certificate on 9th April, 2026, in accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate was issued by MCS Share Transfer Agent Limited, the company's registrar and share transfer agent, dated 8th April, 2026.

Certificate Confirmation Details

MCS Share Transfer Agent Limited confirmed several key compliance aspects in their certificate. The registrar verified that all securities received from depository participants for dematerialization during the quarter were properly confirmed to the depositories. Additionally, they ensured that securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are already listed.

The certificate also confirms that security certificates received for dematerialisation were mutilated and cancelled after due verification by the depository participant. Importantly, the names of the depositories were substituted in the register of members as registered owners within the mandatory 15-day period.

Company and Registrar Information

Hemo Organic Limited, incorporated under CIN L24231GJ1992PLC018224, is headquartered in Ahmedabad, Gujarat. The company's managing director, Vishwambar Kameshwar Singh (DIN: 09822587), signed the submission letter digitally on 9th April, 2026.

MCS Share Transfer Agent Limited, operating under CIN U67120WD2011PLC165872, serves as the company's registrar and share transfer agent. The Ahmedabad-based registrar is located at Shatdal Complex on Ashram Road and was represented by their authorized signatory in issuing the compliance certificate.

Regulatory Significance

This quarterly submission represents standard regulatory compliance for listed companies, ensuring transparency in dematerialization processes and maintaining accurate shareholder records. The certificate validates that the company and its registrar have adhered to SEBI's prescribed timelines and procedures for handling securities dematerialization during the quarter ended 31st March, 2026.